New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

FDA Approves Nucala as First Biologic Treatment for HES

The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause.

3

Research Roundup: Two Types of Parkinson’s Disease and More

Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.

9

Study: SARS-CoV-2 Infection During Pregnancy Does Not Increase Risk of Complications

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy does not appear to increase the risk of complications during delivery or negatively impact the health of newborns, according to a new JAMA study.

10

Opdivo Significantly Improves DFS vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma

Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).